![](images/graphics/blank.gif)
Standard outcomes
-
Soft tissue sarcomas (STS), have significant inter- and intra-tumoral heterogeneity, with poor response to standard neoadjuvant radiotherapy (RT). Achieving a favorable pathologic response (FPR≥95%) from RT is associated with improved patient outcome.
16p
vishanshan
27-06-2024
1
1
Download
-
Patient-centred measurement (PCM) emphasizes a holistic approach wherein the voices of patients are reflected in the standardized use of patient-reported outcome and experience measures and are represented throughout the continuum of measurement activities. Given the challenges of routinely integrating patient self reports into clinical care decisions, the perspectives of all healthcare system stakeholders, especially patients, is necessary to advance the science of PCM.
13p
vishanshan
27-06-2024
1
1
Download
-
The current standard of care in the neoadjuvant setting for high-risk HER2-positive (HER2+) breast cancer is to combine systemic chemotherapy with dual HER2 blockade, trastuzumab and pertuzumab. Targeted therapies have significantly improved outcomes for patients with HER2-positive breast cancer.
8p
vikoch
27-06-2024
1
1
Download
-
There are limited and no standard therapies for recurrent glioblastoma. We herein report the antitumour activity and safety of sintilimab, bevacizumab and temozolomide (TMZ) in recurrent glioblastoma.
10p
vikoch
27-06-2024
1
1
Download
-
Changes in medical practice are needed to improve the diagnosis of monogenic forms of selected common diseases. This article seeks to focus attention on the need for universal genetic testing in common diseases for which the recommended clinical management of patients with specific monogenic forms of disease diverges from standard management and has evidence for improved outcomes.
10p
viellison
28-03-2024
4
2
Download
-
Part 1 book "Fundamentals of nursing - standards and practice" includes content: Evolution of nursing and nursing education; nursing theory; research and evidence based practice; health care delivery, quality and the continuum of care; critical thinking, decision making and the nursing process; assessment; nursing diagnosis; planning and outcome identification; implementation; evaluation... and other contents.
452p
muasambanhan08
23-02-2024
7
1
Download
-
The long-term oncologic outcomes after laparoscopic and open procedures for patients with intermediate- and high-risk endometrial cancer (EC) remain unclear. Accordingly, laparoscopy cannot still be recommended as the standard choice for intermediate- and high-risk EC.
8p
vileonardodavinci
23-12-2023
2
2
Download
-
Postoperative stereotactic radiosurgery (SRS) is a standard management option for patients with resected brain metastases. Preoperative SRS may have certain advantages compared to postoperative SRS, including less uncertainty in delineation of the intact tumor compared to the postoperative resection cavity, reduced rate of leptomeningeal dissemination postoperatively, and a lower risk of radiation necrosis.
8p
vileonardodavinci
23-12-2023
4
2
Download
-
Brain metastases (BM) are a common complication in advanced cancer patients, and extremely challenging to treat. Consequently, whole brain radiotherapy (WBRT) remains the standard palliative intervention for patients with BM. The present study set to evaluate the clinical benefits of WBRT by assessing the quality of life (QoL) in WBRT-treated patients with BM, in Nigeria.
10p
vileonardodavinci
23-12-2023
2
2
Download
-
One-year S-1 or six-month capecitabine/oxaliplatin (CAPOX) has been the standard adjuvant chemotherapy for gastric cancer (GC). We investigated outcomes according to the cycles of adjuvant chemotherapy, using data from the Korean Health Insurance and Assessment Service.
8p
vialfrednobel
23-12-2023
5
3
Download
-
Stereotactic radiosurgery (SRS) has become a standard approach for the treatment of patients with few metastatic brain lesions. This study aimed to compare the survival outcomes and intracranial local control in NSCLC patients with 1–4 BMs who are treated with SRS using linear accelerators (LINAC-SRS), whole-brain radiotherapy (WBRT), or WBRT plus radiotherapy boost (WBRT+RTB).
14p
vialfrednobel
23-12-2023
3
3
Download
-
ICIs have become the standard treatment for advanced NSCLC patients. Currently, PD-L1 is the most widely useful biomarker to predict ICI efficacy, but the sensitivity and specificity are limited. Therefore, the useful predictive biomarkers of ICI efficacy is urgently needed.
14p
vialfrednobel
23-12-2023
4
3
Download
-
Immunotherapy targeting the PD-1/PD-L1 pathway is a standard of care in a number of metastatic malignancies, but less than a fifth of patients are expected to respond to ICIs (Immune Checkpoint Inhibitors). In a clinical trial, combining the anti-TIGIT (T cell immunoreceptor with Ig and ITIM domains) Mab (monoclonal antibody) tiragolumab with atezolizumab improved outcomes in non-small cell lung cancer.
15p
vialfrednobel
23-12-2023
8
4
Download
-
Gastric cancer (GC) remains among the most common and most lethal cancers worldwide. Peritoneum is the most common site for distant dissemination. Standard treatment for GC peritoneal metastases (PM) is a systemic therapy, but treatment outcomes remain very poor, with median overall survival ranging between 3-9 months.
9p
vialfrednobel
23-12-2023
5
3
Download
-
Nanoliposomal irinotecan plus fluorouracil/leucovorin (5-FU/LV) is a standard second-line therapy for patients with pancreatic cancer. Identification of biomarkers is important to determine appropriate treatment strategies. We investigated the clinical practice outcomes and biomarkers associated with the nanoliposomal irinotecan plus 5-FU/LV regimen.
8p
vischultz
20-10-2023
3
1
Download
-
Neoadjuvant chemotherapy (NAC) followed by surgery is the standard treatment for locally advanced esophageal squamous cell carcinoma (ESCC). Chemoradiotherapy (CRT) is an alternative treatment approach. However, both treatments are associated with toxicity, and the optimal treatment for older patients with ESCC is unknown.
11p
vischultz
20-10-2023
3
2
Download
-
Gemcitabine (Gem) has been a standard first-line drug for pancreatic cancer (PCa) treatment; however, Gem’s rapid metabolism and systemic instability (short half-life) limit its clinical outcome. The objective of this study was to modify Gem into a more stable form called 4-(N)-stearoyl-gemcitabine (4NSG) and evaluate its therapeutic efficacy in patient-derived xenograft (PDX) models from PCa of Black and White patients.
21p
visharma
20-10-2023
2
2
Download
-
Immunotherapy (IO) has become a standard of care for treating various types of metastatic cancers and has significantly improved clinical outcome. With the exception of metastatic melanoma in complete response for which treatment can be stopped at 6 months, these treatments are currently administered until either disease pro‑ gression for some IO, 2 years for others, or unacceptable toxicity.
10p
visharma
20-10-2023
6
3
Download
-
Lymph node (LN) metastasis is the earliest sign of metastatic spread and an established predictor of poor outcome in gallbladder cancer (GBC). Patients with LN positive GBC have a significantly worse survival (median survival- 7 months) than patients with LN negative disease (median survival-~23 months) in spite of standard treatment which includes extended surgery followed by chemotherapy, radiotherapy and targeted therapy.
15p
visharma
20-10-2023
4
2
Download
-
Laparoscopic adrenalectomy has emerged as the standard treatment for adrenal tumors. Although the application of high - resolution cameras has enhanced visualization in conventional two - dimensional laparoscopy, it has not fully overcome the limitations of depth perception and spatial recognition. This study aims to evaluate the outcome of three - dimensional laparoscopic adrenalectomy.
6p
vischultz
17-10-2023
4
2
Download
CHỦ ĐỀ BẠN MUỐN TÌM
![](images/graphics/blank.gif)